Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro
ADCs are designed to deliver chemotherapy directly to tumours. However, more than 95% of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity.